Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Weight-Loss drug tirzepatide tested to boost healthy births after IVF

NCT ID NCT07811895

Symptom relief Sponsor: RenJi Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time

Summary

Researchers are testing whether a weight-loss drug called tirzepatide, given for 16 weeks before a frozen embryo transfer, can improve the chance of a healthy birth in women with obesity. The trial enrolls women aged 20 to 40 with a BMI of 28 or higher who plan to have a frozen embryo transfer and have at least one embryo available. The main goal is to see how many women have a good birth outcome, defined as a live birth at 37 weeks or later with a normal birth weight and no major birth defects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirzepatide, a dual GIP/GLP-1 receptor agonist drug
What this could lead to
If it works, tirzepatide before frozen embryo transfer could become a way to improve the chance of a healthy baby for women with obesity.
What could go wrong
This is a large but still experimental approach. Weight-loss drugs can cause nausea, vomiting, and other side effects, and it is not yet clear whether short-term use before transfer improves birth outcomes or is safe in this setting.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,510 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 40 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women aged 20-40 years; 2. Body Mass Index(BMI) ≥ 28kg/m2; 3. Women who intend to undergo frozen-thawed embryo transfer; 4. At least one embryo available for transfer; 5. Be capable of giving informed consent. Exclusion Criteria: 1. Women who have been diagnosed with diseases affecting uterine cavity or endometrial receptivity; 2. Presence of endocrine disorders that may significantly affect body weight; 3. Use of drugs that may cause significant weight changes within 8 weeks before screening; 4. Presence of contraindications to the use of dual GIP/GLP-1 receptor agonist; 5. Previous bariatric surgery (e.g., gastric bypass) or planning to undergo such surgery during the study period; 6. Serum triglycerides (TG) \> 5.64mmol/L; 7. Calcitonin≥50 ng/L; 8. Presence of medical contraindications to assisted reproductive technology and/or pregnancy; 9. Any other condition considered inappropriate for participation by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Frozen embryo transfer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Frozen embryo transfer Obesity Tirzepatide

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • RenJi Hospital

    Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.